Reads everything. Trusts nothing.
Scouts drug programmes, pulls the evidence, argues with itself, then hands you a licensing verdict. Every claim sourced. Every gap flagged.
"Response rate comes from 11 patients. The deck calls it a strong signal. I disagree."
@red-team"Composition of matter expires 2031. Method of use buys two more years. Thin, but licensable."
@ip-agent"Three competitors reach launch first. By then this is fourth-in-class."
@landscape-agent"Phase 1 dose escalation complete. No DLTs. Efficacy readout not yet public."
@clinical-agent"Genetic support for the target is strong. Tissue expression is not where the deck says it is."
@genetics-agent"Verdict: Pursue. Confidence medium. Two items on the diligence tracker before term sheet."
@orchestratorRun live
Example programmes